Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266083 · ClinicalTrials.gov registry record · Phase 2
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
A Phase 2 study, sponsored by Sellas Life Sciences Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01266083 is a Phase 2 study that has completed, run by Sellas Life Sciences Group. The registered enrollment target is 22 participants.
The verdict
NCT01266083, a Phase 2 study, has completed, sponsored by Sellas Life Sciences Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This trial will assess the safety and efficacy of vaccination with galinpepimut-S (GPS), a WT1 peptide vaccine, in patients who are in complete remission from leukemia. Participants will receive vaccinations with GPS every 2 weeks for 10 weeks (a total of 6 vaccinations). In the absence of disease recurrence at Week 12 and if clinically stable after the first 6 vaccinations, participants may continue to receive up to six more vaccinations every month.
Interventions
- BIOLOGICAL GM-CSF
- BIOLOGICAL Galinpepimut-S
- OTHER Montanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-01-14 |
| Est. Completion | 2016-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01266083
The ClinicalTrials.gov registry entry for NCT01266083 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sellas Life Sciences Group, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GM-CSF is the first listed.
NCT01266083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01266083 about?
NCT01266083 is a clinical study titled "WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)". This trial will assess the safety and efficacy of vaccination with galinpepimut-S (GPS), a WT1 peptide vaccine, in patients who are in complete remission from leukemia. Participants will receive vaccinations with GPS every 2 weeks for 10 weeks (a total of 6 vaccinations). In the absence of disease ...
What is the current status of trial NCT01266083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2011-01-14. Estimated completion is 2016-09-30.
What interventions are being tested in trial NCT01266083?
The interventions under investigation include: GM-CSF (BIOLOGICAL), Galinpepimut-S (BIOLOGICAL), Montanide (OTHER).
Who is sponsoring clinical trial NCT01266083?
This trial is sponsored by Sellas Life Sciences Group, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.